Newsroom | 84391 results

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria’s common stock on May 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted...

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics to Present on RNA-guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company will also showcase its updated Intelligent Radiation Therapy (iRT), a software solution that standardizes complex workflows, helping to enable a shorter timeline from diagnosis to treatmen...

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, a clinical-stage pharmaceutical and medical device company, announced today that it has achieved a critical milestone in its effort to reduce dependency on cold-storage for vaccines. In partnership with the nonprofit International AIDS Vaccine Initiative, Turn Therapeutics has validated a standardized assay and demonstrated 100% recovery of vesicular stomatitis virus (VSV) -- a widely used viral backbone in vaccine development -- after both 24 an...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. Event Details: Title: Aditxt Weekly Update Date: Friday, May 2, 2025 Time:...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company’s common stock to 13 new employees (t...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonis...

フィラデルフィア--(BUSINESS WIRE)--（ビジネスワイヤ） -- PCIファーマ・サービシズ（以下「PCI」）は、革新的なバイオ医薬品治療に特化した世界有数の開発・製造受託機関（CDMO）である味の素アルテア（以下「アルテア」）の買収を完了しました。アルテアは、米国を拠点とする無菌充填製剤CDMOであり、日本の味の素株式会社の子会社です。今回の買収は、米国と欧州における施設を対象とした複数年にわたる投資戦略の礎となるものです。米国では、アルテアの資産がPCIの既存の無菌充填および高度な薬物送達オペレーションと統合され、サンディエゴにプレフィルド・シリンジおよびカートリッジ用の最新鋭の大規模無菌設備を備えた世界クラスの大規模製造拠点が形成されます。アルテアのキャンパスは、カスタマイズ可能でスケーラブルなオリゴヌクレオチドおよびペプチドの製造に特化しており、ナノ粒子、mRNA、MAB、タンパク質、その他の生物製剤を含む広範な注射剤のための複雑な製剤と凍結乾燥のPCI社の既存製造をサポートします。 この買収に関する追加情報は、PCIのウェブサイトの専用ウェブページでご覧いただ...